Amedisys Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall Street ends lower as tech shares slip
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Taiwan prosecutors detain Super Micro employees over chip exports
Amedisys (AMED) PT Raised to $64 at Jefferies
November 8, 2017 8:35 AM ESTJefferies raised its price target on Amedisys (NASDAQ: AMED) to $64.00 (from $60.00) while maintaining a Buy rating following Q3.
Analyst Brian Tanquilut said the 5% SS increase in Medicare episodes highlights early traction the company is seeing with its revamped sales force and growth initiatives.
... More